HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy

Brouard, Cécile; Saboni, Leïla; Gautier, Arnaud; Chevaliez, Stéphane; Rahib, Delphine; Richard, Jean-Baptiste; Barin, Francis; Larsen, Christine; Sommen, Cécile; Pillonel, Josiane; Delarocque-Astagneau, Elisabeth; Lydié, Nathalie; Lot, Florence

doi:10.1186/s12879-019-4493-2

Table 3 Estimated prevalence of CHC and CHB according to socio-demographical characteristics and risk exposure factors in the general population aged 18-75 years, BaroTest, mainland France, 2016

From: HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy

Characteristics		Chronic hepatitis C^a (n = 6,931)			Chronic hepatitis B^b (n = 6,945)
Characteristics		wBT%	95%CI	p	wBT%	95%CI	p
Total		0.30	0.13-0.70		0.30	0.13-0.70
Gender	Men	0.34	0.14-0.84	NS	0.28	0.12-0.63	NS
Gender	Women	0.26	0.05-1.21	NS	0.32	0.08-1.28	NS
Age (in years)	18-45	0.08	0.01-0.45	< 0.05	0.10	0.03-0.29	< 0.05
Age (in years)	46-75	0.51	0.20-1.32	< 0.05	0.51	0.19-1.34
Educational level	< secondary school certificate	0.52	0.19-1.37	< 10 ⁻²	0.18	0.06-0.53	NS
Educational level	≥ secondary school certificate	0.08	0.03-0.22	< 10 ⁻²	0.19	0.10-0.38	NS
Household monthly income	1st tercile (low)	0.74	0.27-1.96	< 10 ⁻³	0.63	0.20-1.96	< 0.05
Household monthly income	2nd/3rd tercile	0.07	0.03-019		0.14	0.07-0.27
Place of residence	Ile-de-France (Paris region)	0.31	0.05-1.79	NS	0.16	0.04-0.60	NS
Place of residence	Other regions	0.30	0.11-0.78	NS	0.34	0.13-0.84	NS
Place of birth	Mainland France	0.35	0.15-0.82		0.14	0.08-0.26	< 10 ⁻³
	French Overseas administrative areas	0			0
	Europe	0			0.96	0.13-6.48
	Maghreb	0			0
	Sub-Saharan Africa	0			5.81	0.95-28.5
	Other countries	0			0.73	0.10-5.10
Health Insurance coverage for low-income persons^c	Yes	0.66	0.09-4.5	NS	1.98	0.43-8.59	< 10 ⁻³
Health Insurance coverage for low-income persons^c	No	0.27	0.10-0.69	NS	0.16	0.09-0.28
Drug use during lifetime	Yes, intravenous use with or without nasal use	12.1	2.93-38.4	< 10 ⁻³	0		NS
	Yes, nasal use only	0			0.24	0.03-1.71
	No	0.24	0.09-0.67		0.31	0.13-0.74
Blood transfusion before 1992	Yes	1.12	0.24-5.03	NS			NS
Blood transfusion before 1992	No	0.24	0.09-0.67	NS			NS
Healthcare or stays ≥3 months in Africa, Asia or Middle East	Yes	0.33	0.06-1.85	NS	0.95	0.14-6.01	NS
	No	0.29	0.11-0.76	NS	0.21	0.11-0.40	NS
Tattooing or piercing without single-use materials	Yes	2.55	0.36-15.9	< 10 ⁻²	0.9	0.10-6.17	NS
Tattooing or piercing without single-use materials	No	0.25	0.10-0.64	< 10 ⁻²	0.29	0.12-0.70	NS
Lived with or sexual intercourse with an HBV infected person	Yes			NS	0.68	0.20-2.34	NS
	No			NS	0.28	0.11-0.72	NS
Sex with other men during lifetime^d	Yes	0.31	0.04-2.19	NS	3.39	0.84-12.7	< 10 ⁻³
Sex with other men during lifetime^d	No	0.34	0.14-0.87	NS	0.16	0.06-0.39
Sexually transmitted infection(s) in the previous 12 months^e	Yes	0.46	0.06-3.22	NS	1.16	0.16-7.82	NS
	No	0.3	0.13-0.72		0.30	0.12-0.72
HBV vaccination	Yes	0.17	0.05-0.58	NS	0.36	0.09-1.39	NS
HBV vaccination	No	0.47	0.16-1.38	NS	0.29	0.13-0.63	NS

wBT% BaroTest weighted percentage, aPR adjusted prevalence ratio, 95% CI 95% confidence interval, NS Not significant
^aDefined as positive HCV RNA
^bDefined as positive HBs Ag
^cIncludes Complementary Universal Health Insurance (CMU, which is free insurance for low-income persons) and State Medical Assistance (AME, which is free insurance for low-income irregular migrants)
^dAmong men who reported having had sexual relations in their lifetime (with men or women)
^eAmong individuals who have already had sexual relations. Mycosis are excluded
The distributions are significantly different for numbers in bold

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us